Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study

British Journal of Psychiatry

Volumn 197, Issue 4, 2010, Pages 285-290

  Morgan, Celia J A ^a   Schafer, Gráinne ^a   Freeman, Tom P ^a   Curran, H Valerie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; DRONABINOL;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; CANNABIS SMOKING; CLINICAL ASSESSMENT; COGNITION; DRUG INTOXICATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; NEUROPROTECTION; SALIVA ANALYSIS;

ADOLESCENT; ALCOHOL DRINKING; ANALYSIS OF VARIANCE; CANNABIDIOL; CANNABINOIDS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MARIJUANA SMOKING; MEMORY; MEMORY DISORDERS; MENTAL RECALL; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, CANNABINOID, CB1; SALIVA; TETRAHYDROCANNABINOL; VERBAL LEARNING; YOUNG ADULT;

EID: 77957687873     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.077503     Document Type: Article

References (35)

1. NatCen. Health Survey Findings for England 2008. National Centre for Social Research, 2009 (http://www.natcen.ac.uk/study/health-survey-for-england- 2008/findings).
2. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2006: The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, 2006.
3. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28. (Pubitemid 47094993)
4. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007; 17: 347-61. (Pubitemid 47498179)
5. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 2002; 164: 61-70. (Pubitemid 35203843)
6. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72.
7. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9- tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008; 33: 2505-16.
8. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39: 421-9.
9. Guimares FS, Chiaretti TM, Graeff FG. Antianxiety effects of cannabidiol in the elevated plus-maze. Psychopharmacology 1990; 100: 558-9.
10. Hermann D, Sartorius A, Welzel H, Walter S, Skopp G, Ende G, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 2007; 61: 1281-9. (Pubitemid 46726261)
11. Hardwick S, King LA. Home Office Cannabis Potency Study. Home Office Scientific Development Branch, 2008.
12. Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-7.
13. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
14. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experience with the drug. Br J Addict 1992; 87: 1161-72.
15. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607-14.
16. Wechsler D. Wechsler Test of Adult Reading. Psychological Corporation, 2001.
17. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991; 17: 555-64.
18. Wilson B, Cockburn J, Baddeley A. The Rivermead Behavioural Memory Test. Thames Valley Test Company, 1985.
19. Wilding EL, Rugg MD. An event-related potential study of recognition memory with and without retrieval of source. Brain 1996; 119: 889-905. (Pubitemid 26237186)
20. Mason OJ, Morgan CJ, Stefanovic A, Curran HV. The Psychotomimetic States Inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 2008; 103: 138-42.
21. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
22. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-29.
23. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72. (Pubitemid 38982249)
24. Ilan AB, Gevins A, Coleman M, Elsohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 2005; 16: 487-96. (Pubitemid 41404822)
25. Wise LE, Thorpe AJ, Lichtman AH. Hippocampal CB(1) receptors mediate the memory impairing effects of delta(9)-tetrahydrocannabinol. Neuropsychopharmacology 2009; 34: 2072-80.
26. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2009; 35: 764-74.
27. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006; 188: 425-44. (Pubitemid 44498214)
28. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-4. (Pubitemid 34851398)
29. de Oliveira AL, de Oliveira LF, Camboim C, Diehl F, Genro BP, Lanziotti VB, et al. Amnestic effect of intrahippocampal AM251, a CB1-selective blocker, in the inhibitory avoidance, but not in the open field habituation task, in rats. Neurobiol Learn Mem 2005; 83: 119-24. (Pubitemid 40255141)
30. Watts FN, Cooper Z. The effects of depression on structural aspects of the recall of prose. J Abnorm Psychol 1989; 98: 150-3. (Pubitemid 19134402)
31. Horwitz JE, McCaffrey RJ. Effects of a third party observer and anxiety on tests of executive function. Arch Clin Neuropsychol 2008; 23: 409-17.
32. Mason O, Morgan CJ, Dhiman SK, Patel A, Parti N, Patel A, et al. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med 2009; 39: 951-6.
33. Hermann D, Sartorius A, Welzel H, Walter S, Skopp G, Ende G, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 2007; 61: 1281-9. (Pubitemid 46726261)
34. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 488-91.
35. Cappell H, Kucher E, Webster CD. Some correlates of marihuana self-administration in man: a study of titration of intake as a function of drug potency. Psychopharmacology 1973; 29: 177-84.